UNSPSC 51162741: Taurosteine

This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 43A07PH183. European Medicines Agency schedules Taurosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10840MIG. Taurosteine generally arises in the molecular formula C7H9NO4S2.

UNSPSC 51162741 Taurosteine is a Commodity code that captures state and local procurement of specialized pharmaceutical and medical products for institutional healthcare delivery, particularly parenteral nutrition solutions, intravenous fluids, and related injectable pharmaceuticals for correctional and community health settings. State and local governments sourcing under this code include departments of corrections, county health departments, and other public health authorities. The Washington State Department of Corrections (DOC) represents the primary recent buyer, soliciting parenteral products and services through an RFQ (RFQQK13020, due October 7, 2026) that specifies total parenteral nutrition (TPN and PPN) solutions, intravenous solutions, and controlled substances for medically necessary healthcare to incarcerated individuals across eight correctional facilities. DOC requires suppliers to demonstrate documented experience preparing and delivering IV solutions, monitoring patient lab results, and adjusting PN preparations, with strict delivery windows (PN bags within 24 hours of order; other parenteral products within 8 hours for the first 24-hour supply). The solicitation encourages participation from small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), with an aspirational 5% Small and Diverse Business Goal and mandatory Subcontractor Inclusion Plans identifying qualified minority-owned, women-owned, and disadvantaged subcontractors where economically prudent.

Recent activity centers in the Pacific Northwest and Southeast, with the Washington State DOC opportunity representing the primary current demand signal and a Seminole County, Florida IFB (IFB60459723LAS, originally due July 26, 2023, though the post date of June 30, 2026 suggests a reposting or amendment) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually on a two-year term with one-year renewal option. The Washington solicitation spans three regions (West, Central, and East) with DOC anticipating multiple contractor awards (up to three bidders per region) under a contract term running November 26, 2026 through June 30, 2030, with fixed pricing through the initial two-year term. Bidders must meet Washington State business licensure requirements, pass Washington State Patrol NCIC clearance for all service employees, and maintain specified insurance (Commercial General Liability $1 million per occurrence / $2 million aggregate, Professional Liability $2 million per occurrence / aggregate, Business Automobile Liability $1 million per occurrence / $2 million aggregate, and Cyber Liability $2 million per occurrence / aggregate). A pre-bid conference is scheduled for September 23, 2026, with questions due September 22, 2026.